[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaccination\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaccination":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,43,75,104,130,153,181,207,238,261,288,321,351,382,415,442,472,498],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100643155","sleep-and-adolescent-vaccine-immunogenicity-pilotobservational-study-100643155",false,"NCT07636525","Sleep and Adolescent Vaccine Immunogenicity Pilot\u002FObservational Study","Sleep and Adolescent Vaccine Immunogenicity (SAVI) Pilot Study","SAVI","Inclusion Criteria:\n\n* Healthy 11-12 years olds who have neither had initial meningococcal vaccination nor known exposure to meningococcal illness.\n\nExclusion Criteria:\n\n* Condition or treatment resulting in immunosuppression\n* Prior severe vaccine reaction\n* Symptoms of clinical insomnia or organic sleep disorder\n* Known neurologic condition or intellectual\u002Fdevelopmental disability\n* Use of a medication that impacts sleep\n* Average nightly sleep of 8-8.99 hours (between the two groups)\n* Daily intake of \\>1 coffee or \"energy drink\" or \\>2 caffeinated sodas.",true,"ALL","11 Years","12 Years",{"count":22,"type":23},66,"ESTIMATED","OBSERVATIONAL","The main reason for this research study is to understand whether the sleep habits of 11-12 years-olds impact their response to a vaccine. The vaccine is called MCV4. It protects against meningococcal illness, which is rare but can be severe. The American Academy of Pediatrics recommends that the vaccine be given at age 11 or 12. The vaccine has been approved for youth in this age range for over 20 years and is one of the vaccines that primary care doctors typically give around this age. However, nobody has studied how sleep affects children's response to it. This could be important because research on adults suggests that sleep affects the immune system. We want to look at that issue in a younger age range.\n\nParticipating families will be asked to have their child keep their regular sleep schedule during the 5-week study, without much variation. During that time, they will wear a special wristwatch at night to track their sleep. Each day they will fill out a short online form. They and a parent\u002Fguardian will come to Cincinnati Children's twice. Each visit will last 1 - 1 ½ hours. The first visit will happen at the end of the 1st week. The second is at the end of the 5th week. During visits, they will fill out forms and we will get data from the wristwatch. During the first visit, the participating child would get the vaccine. During the second, they will have a blood test.",[27],"Vaccination",[29],"Sleep","RECRUITING","2026-06-03",{"date":33,"type":34},"2026-06-09","ACTUAL",{"date":36,"type":23},"2026-07",{"date":38,"type":23},"2027-07",{"name":40,"class":41},"Children's Hospital Medical Center, Cincinnati","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":17,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100639425","optimax-will-test-whether-sq-lns-incentivises-vaccination-uptake-in-rural-chad-and-niger-with-a-cost-effectiveness-analysis-it-will-also-look-at-whether-having-received-sq-lns-before-becoming-malnourished-leads-to-better-outcomes-for-children-treated-under-the-optima-protocol-100639425","NCT07592260","OptiMAx Will Test Whether SQ-LNS Incentivises Vaccination Uptake in Rural Chad and Niger, With a Cost Effectiveness Analysis. It Will Also Look at Whether Having Received SQ-LNS Before Becoming Malnourished Leads to Better Outcomes for Children Treated Under the OptiMA Protocol.","OptiMAx: Incentivizing EPI Vaccination Via Distribution of SQ-LNS Nutritional Supplementation to Children From Age 6-11 Months Until 18 Months of Age in Rural Chad and Niger, With a Cost Effectiveness Analysis Protocol for a Research Study Nested in the OptiMA Research Study in Ngouri Health District, Lake Region, Chad and Mirriah Health District, Zinder Region, Niger","OptiMAx","Inclusion Criteria:\n\n* All non-malnourished children between 6 and 12 months of age will be eligible for SQ-LNS supplementation until they reach 18 months of age.\n\nFor the annual household surveys,\n\n* Children aged 6 to 59 months will be surveyed on MUAC status and other malnutrition-related issues, while the immunization analysis will focus on children aged 12 to 23 months;\n* With the informed oral consent of the parents or legal guardian ;\n* Reside in the neighborhoods included in the study.\n\nFor the mixed-methods process evaluation and gender sub-study (to be carried out in the months following implementation).\n\nInclusion criteria\n\n* OptiMAx intervention personnel (e.g. healthcare staff)\n* A group of mothers of children benefiting from the intervention\n* Male partners\u002Fspouses of parents\n* Community members from the sites targeted by the intervention will be recruited for the focus groups.\n* Non-adherents or parents who choose not to continue nutritional supplementation and\u002For vaccination despite their availability under the program will be recruited for interviews.\n* Husbands\u002Fmale partners of non-members will also be surveyed.\n\nExclusion Criteria:\n\n* Age-eligible children with MUAC \\\u003C125 or edema will first be treated for acute malnutrition with OptiMA and then resume supplementation with SQ-LNS.\n\nThere is no exclusion criteria for the annual household surveys\n\nExclusion criteria for the mixed-methods process evaluation\n\n\\- Parents or guardians under 15 years of age.","6 Months","59 Months",{"count":54,"type":23},20000,"INTERVENTIONAL",[57],"NA","Malnutrition and infectious disease form a vicious circle, posing a double threat to vulnerable children in low- and middle-income countries. Malnutrition makes children more vulnerable to infectious diseases, while infectious diseases increase the risk of malnutrition. When caught in this cycle, children are far more likely to die or suffer adverse effects on their health and development. High rates of wasting and low immunization coverage also constitute a weakening double burden for already fragile health systems. Every year in these contexts, hundreds of thousands of children are treated for severe wasting, while at the same time suffering repeated and prolonged epidemics of vaccine-preventable diseases such as measles. Rural areas of Chad and Niger are at the heart of this dynamic, recording some of the worst indicators of malnutrition and low vaccination coverage rates.\n\nSmall-quantity lipid-based nutritional supplements (SQ-LNS) are a category of ready-to-use, nutrient-dense food supplements fortified with micronutrients, designed to prevent malnutrition and improve child survival, growth and development. A recent meta-analysis on SQ-LNS reveals that giving a child just one sachet of SQ-LNS a day for a year can reduce the risk of mortality by 27%, iron-deficiency anemia by 64%, severe wasting by 31% and severe stunting by 17%. The recent World Health Organization (WHO) guideline on complementary feeding of infants and young children aged 6 to 23 months recently recommended the use of SQ-LNS in certain contexts of food insecurity, based on evidence deemed \"very safe\".\n\nThe distribution of SQ-LNS is also promising as an incentive for vaccination, as well as for other health services, such as participation in infant growth monitoring programs. Various operational experiences suggest that it is likely to have an impact on increasing vaccination coverage, and a modeling simulation suggests that it would lead to a significant reduction in measles morbidity and mortality.\n\nThe main objective of OptiMAx is to estimate the effectiveness of a mass SQ-LNS supplementation program coupled with the routine immunization program compared with the routine immunization program alone in terms of vaccination coverage against pentavalent 1 (Niger) and measles 1 (Chad), after 12 months of program implementation, in children aged 12 to 23 months as part of an annual cross-sectional household survey.\n\nSecondary objectives include:\n\n* Estimate the effectiveness of a mass SQ-LNS supplementation program combined with the routine Essential Program on Immunization (EPI) compared with the routine EPI alone in children aged 6-18 months, after 12 months of program implementation, in terms of 1) coverage of pentavalent 3 vaccine, malaria and other childhood vaccines, 2) on-time immunization for age-eligible children.\n* Evaluate the feasibility and reliability of combining measles and pentavalent coverage measurements during annual MUAC-family training campaigns;.\n* Evaluate outcomes of acutely malnourished children who received SQ-LNS supplementation prior to RUTF treatment (as part of their inclusion in the OptiMA study) versus those who did not receive SQ-LNS supplementation\n\nThe specific objectives of the process evaluation (with a sub-study on gender), modeling and economic evaluation are as follows:\n\n1. Conduct a process evaluation of the OptiMAx intervention to understand how it works, for whom and where;\n2. Understand to what extent and how gender-related facilitations and barriers affect the interaction and uptake of intervention, both on the demand side (health-seeking\u002Fintervention behaviors) and the supply side (provision of intervention services).\n3. Estimate the health impact of the OptiMAx intervention, in terms of nutrition and vaccine-preventable diseases, using mathematical modeling approaches.\n4. Quantify the relative costs associated with the OptiMAx intervention compared with the costs associated with existing vaccination activities in Mirriah, Niger, and Ngouri, Chad.\n5. Estimate the cost-effectiveness of the OptiMAx intervention in Mirriah, Niger, and Ngouri, Chad.",[60,27],"Malnutrition Severe",[62,63,64],"routine immunization","SQ-LNS supplementation","acute malnutrition","2026-05-11",{"date":67,"type":34},"2026-05-18",{"date":69,"type":34},"2025-05-01",{"date":71,"type":23},"2026-12",{"name":73,"class":41},"Alliance for International Medical Action",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":17,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":42},"100445320","vaccine-responses-to-sars-cov-2-and-other-emerging-infectious-diseases-100445320","NCT05078905","Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases","Longitudinal Observations of Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases","* INCLUSION CRITERIA:\n\nGeneral Inclusion Criteria for All Groups:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study\n2. Age 18 years or older\n3. Hemoglobin \\>= 9.0 grams per deciliter (g\u002FdL) or \\>= 11.2 for women who are pregnant.\n4. Willingness to give consent for the storage of blood samples for research\n5. Ability of subject to understand and the willingness to sign a written informed consent document\n\nInclusion Criteria for Primary (New) Vaccination Group:\n\n1\\. No history of having received a dose of the vaccine for the infectious disease being studied. Subjects who have enrolled under another Laboratory of Immunoregulation (LIR) protocol and had samples drawn prior to vaccination will also be eligible for enrollment.\n\nInclusion Criteria for Secondary (Booster) Vaccination Group:\n\n1\\. Willingness to return for baseline research blood collection prior to booster vaccination.\n\nEXCLUSION CRITERIA:\n\n1. Current abuse of alcohol or other drugs that, in the judgement of the Principal Investigator (PI) could interfere with patient compliance.\n2. Any medical or mental health condition that, in the judgement of the PI, would make the volunteer unable to participate in the study.","18 Years",{"count":84,"type":23},1200,"Background:\n\nVaccines against SARS-CoV-2, the virus that causes COVID-19, have been highly effective against preventing severe disease. But the protective effects of these vaccines appear to wane over time. Researchers want to learn why.\n\nObjective:\n\nTo learn more about how the immune system responds to vaccines against infections like SARS-CoV-2.\n\nEligibility:\n\nHealthy adults ages 18 or older who are scheduled to receive either a new vaccine or a booster shot against SARS-COV-2 or another emerging infection.\n\nDesign:\n\nParticipants will be screened with a medical history and blood and urine tests.\n\nParticipants will have up to 8 study visits in 1 year. Each visit should last less than 2 hours. At each visit, participants will give blood samples. Some blood samples will be used for genetic testing. They will also give updates on their health.\n\nAfter the first study visit, participants will receive either a first vaccination or a booster shot. They must get the vaccine in their community or workplace. They will not get the vaccine at NIH.\n\nThis study currently focuses on SARS-CoV-2, but it will expand to other infectious diseases as they emerge and become the target of new vaccines.\n\n...",[87,27,88],"COVID-19","Healthy Volunteer",[27,90,87,91,92,93],"Pandemic","Pathogens","Immune Response","Natural History","2026-05-07",{"date":96,"type":34},"2026-05-08",{"date":98,"type":34},"2021-10-13",{"date":100,"type":23},"2050-01-01",{"name":102,"class":103},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":17,"sex":18,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":55,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":42},"100584519","can-stories-encourage-the-elderly-to-vaccinate-combining-viewer-tailored-personal-narrative-videos-with-informational-videos-to-improve-vaccine-uptake-among-older-adults-100584519","NCT06890403","Can Stories Encourage the Elderly to Vaccinate? Combining Viewer-tailored Personal Narrative Videos With Informational Videos to Improve Vaccine Uptake Among Older Adults","Inclusion Criteria:\n\n* U.S. adults aged 50 and older\n\nExclusion Criteria:\n\n* Participants who do not complete the survey\n* Participants who are unable or refuse to view and listen to videos on the participant's device","50 Years",{"count":112,"type":23},6000,[57],"This study will compare the use of informational videos only, personal story videos only, and the combination of both, to see which is most effective in increasing vaccination among older adults.",[27],[117,118,119,120],"vaccine","narrative","communication","videos","2026-02-12",{"date":123,"type":34},"2026-02-13",{"date":125,"type":34},"2025-09-16",{"date":127,"type":23},"2027-01",{"name":129,"class":41},"Johns Hopkins Bloomberg School of Public Health",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":55,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":42},"100561214","facts-tell-and-with-stories-sell-combining-viewer-tailored-personal-human-papillomavirus-hpv-narrative-video-with-hpv-vaccine-information-video-to-improve-hpv-vaccine-uptake-100561214","NCT06587243","\"Facts Tell… and With Stories Sell?\" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake","\"Facts Tell… and With Stories Sell?\" Combining Viewer-tailored Personal HPV Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake","Inclusion Criteria:\n\n* Parents of 11-17 year olds not yet vaccinated against HPV\n\nExclusion Criteria:\n\n* Parents whose adolescent children are already vaccinated against HPV\n* Participants who do not complete the survey\n* Participants who are unable or refuse to view and listen to videos on the participant's device",{"count":138,"type":23},1100,[57],"This study will compare the use of informational videos only, personal story videos only, and the combination of both, to see which is most effective in increasing HPV vaccination.",[27],[143,144,145,146,147],"HPV","Vaccine","Narrative","Communication","Videos",{"date":123,"type":34},{"date":150,"type":34},"2025-11-24",{"date":127,"type":23},{"name":129,"class":41},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":17,"sex":18,"minAge":82,"maxAge":110,"enrollmentInfo":161,"targetDuration":4,"studyType":55,"phases":163,"briefSummary":165,"conditions":166,"keywords":170,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":42},"100580070","phase-4-investigating-gender-and-sex-differences-in-immune-responses-through-vaccination-of-transgender-and-cisgender-persons-100580070","NCT06832514","Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons","An Investigator-initiated, Single-center Academic Study in Healthy Transgender and Cisgender Persons Aged Between 18 and 50 Years to Investigate Gender and Sex Differences in Immune Responses to Meningococcal Serogroup B Vaccination","Vaxxygender","Inclusion Criteria:\n\n1. Written signed informed consent form (ICF) obtained before any study-related activities.\n2. Participants aged between, and including, 18 and 50 years of age at the time of signing the ICF which equals with the time of the first study intervention.\n3. Participants who are considered to be in good general health as determined by the investigator by medical evaluation including medical history andphysical examination at enrollment.\n4. Participants with a BMI within the range 18.5 to 35 kg\u002Fm2 inclusive at screening.\n5. POCBP (18-50 years of age) who are not pregnant or breastfeeding or planning to become pregnant during the clinical study.\n6. Transgender persons need to be under stable gender-affirming hormone therapy (GAHT) for at least 6 months. Compliance needs to be documented by hormonal lab tests.\n7. POCBP must have a negative urine pregnancy test at each vaccination visit (Visit 1 and Visit 5) Refer to Section 8.6.5 for Pregnancy Testing.\n8. Participants who are willing and able to comply with the study procedures and are capable to comply with the requirements of the protocol (e.g. return for follow-up visits) as determined by the investigator.\n\nExclusion Criteria:\n\n1. Current or previous, confirmed or suspected disease caused by N. meningitidis and N. gonnorrhoea.\n2. Household contact with and\u002For intimate exposure (e.g. sexual or saliva contact) to an individual with laboratory confirmed N. meningitidis infection during life.\n3. Transgender persons in a diagnostic phase (no hormonal intervention) or undergoing treatment based on the suppression of endogenic hormones (e.g. gonadotropin releasing hormone analogues).\n4. Current or previous infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV) as determined by anamnesis and medical history.\n5. Past or current confirmed or suspected immune-suppressive or immune-deficient condition, at the discretion of the investigator, including but not limited to blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders, lupus erythematosus and associated conditions or disorders (e.g. rheumatoid arthritis, scleroderma) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).\n6. History of confirmed hypersensitivity, anaphylaxis and\u002For other severe allergic reactions (e.g., generalized urticaria, angioedema, bronchospasm) to any component of the study vaccine or excipients (sodium chloride, histidine, sucrose, kanamycin and water for injection), medical products, or medical equipment whose use is foreseen in this study, as determined by the investigator.\n7. Clinical conditions representing a contraindication for IM administration and blood draws, as judged by the investigator, e.g. thrombocytopenia or history of bleeding disorder (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties.\n8. History of asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen.\n9. Active malignancy or malignancy within the past 5 years that, in the opinion of the investigator, may affect immune response or participant safety - except for localized and fully treated cancers not requiring long-term therapy such as chemotherapy or radiotherapy (e.g. completely resected basal cell carcinoma, cervical intraepithelial neoplasia, melanoma in situ, early-stage thyroid cancer), based on the investigator's clinical judgement.\n10. History of idiopathic urticaria within the past year.\n11. Currently pregnant, breast-feeding or planning to become pregnant. Cisgender women with permanent infertility due to an alternate medical cause (e.g. documented bilateral oophorectomy, androgen insensitivity, gonadal dysgenesis) are excluded to participate. For individuals with permanent infertility due to an alternate medical cause other than the above, investigator discretion should be applied to determining study entry. Additionally, cisgender women in a postmenopausal state, defined as no menses for 12 months without an alternative medical cause are also excluded to participate. Refer to\n12. Any other clinical condition that, in the opinion of the investigator, could compromise the participant's safety and\u002For compliance with the study protocol (e.g. current or recent (\\\u003C 1 years ago) heavy smoking (\\> 20 cigarettes per day) or daily heavy vaping (equivalent to 20 cigarettes), drug- or alcohol (\\> 15 units for cisgender men and transgender women or \\> 10 units or cisgender women and transgender men per week) abuse\u002Faddiction.\n13. Behavioral or cognitive impairment, unstable psychiatric conditions (e.g. forced admission, suicidal thoughts in the last two year) or other psychiatric disease that, in the opinion of the investigator, may interfere with study compliance, as well as with the subject's ability and\u002For safety to participate in the study. Stable psychiatric conditions (e.g. under-controlled depression) will be evaluated based on the investigators judgement.\n14. Donation of blood or blood products within 90 days prior to the first vaccination visit (Visit 1) until Day 56 (Visit 9).\n15. Previous vaccination against any group B meningococcal vaccine (Bexsero®, Trumenba®) at any time prior to informed consent.\n16. Prior receipt of a live-attenuated vaccine in the 28 days prior to administration of the 4CMenB vaccine, within 14 days for subunit or inactivated vaccines or planning to receive a vaccine in between the first and second vaccine administration, as well as 28 days following administration of the second 4CMenB vaccine dose.\n17. Currently participating in another clinical study, or planning to participate in another study during the study period, or administration of any investigational drug or medical device in the 28 days prior to study vaccination.\n18. Prior receipt of blood, blood-derived products or immunoglobulins in the 6 months prior to administration of the study vaccine, or planning to receive such product during the study period.\n19. Chronic administration (defined as 14 consecutive days in total) of immunosuppressants (e.g. corticosteroids (PO\u002FIV\u002FIM) or other immune-modifying drugs (e.g. antineoplastic agents, radiotherapy) during the period starting 90 days prior to vaccination or planned administration during the study (excluding topical, inhaled and intranasal preparations and intra-articular injections). For corticosteroids, this will mean prednisone ≥ 20 mg\u002Fday, or equivalent.\n20. POCBP (cisgender women and transgender men) who use the following contraceptive methods will not be included in the study\n\n    * Oral, injectable, intravaginal (i.e. intravaginal ring) or transdermal combined (oestrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation.\n    * Oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation.\n21. Current anti-tuberculosis prophylaxis or therapy.\n\n25\\. Participants with a history of any medical conditions that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the participants when participating in the study.",{"count":162,"type":23},250,[164],"PHASE4","Sexual differences are a well-established source of biological variation in immune system functioning, with men often displaying lower adaptive immune responses (e.g. antibody production) to infections and vaccinations compared to women. The impact of sex and gender on immune responses and immune functioning warrants more in-depth investigation. This study is an investigator-initiated project aimed at prospectively assessing the immune response towards a vaccine in transgender and cisgender individuals. Transgender individuals retain their chromosomal sex while undergoing a significant hormonal shift that aligns with their experienced gender. Immune responses induced by the four-component meningococcal serogroup B (4CMenB; Bexsero®) vaccine will be evaluated in transgender individuals and compared with responses observed in cisgender individuals. Both humoral and cellular immune responses induced by two doses of the 4CMenB vaccine will be quantified and analysed. This approach is expected to provide new insights into the effects of gender and sex differences on innate and adaptive immune responses.",[167,168,169,27],"Meningococcal Meningitis, Serogroup B","Transgender Persons","Sex Differences in Immune Response",[171],"Gender","2026-01-15",{"date":174,"type":34},"2026-01-20",{"date":176,"type":34},"2025-01-31",{"date":178,"type":23},"2026-12-31",{"name":180,"class":41},"University Ghent",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":17,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":55,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":42},"100611088","arise-at-umass-chan-100611088","NCT07236034","ARISe at UMass Chan","ARISe at UMass Chan: Remote Eye Tracking Study of Vaccine Messaging in Rural Populations","ARISe","Inclusion Criteria:\n\n* Age 18+\n* Living in New England state (CT, MA, ME, NH, VT RI) in a zip code as defined by each individual state's definition of rural\n* Able to read and write in English\n* Access to an internet connected computer or laptop with a web-camera\n\nExclusion Criteria:\n\n* N\u002FA",{"count":190,"type":23},700,[57],"The goal is to identify the most impactful strategies for capturing attention and enhancing effectiveness of vaccine promotion messages. This will be done using an online survey that employs remote eye-tracking and self report measures to evaluate response to sample vaccine promotion social media content in rural populations in New England. Participants will be randomly assigned into one of 14 conditions in a 2(source: expert vs. influencer) by 7 (themes: constructs from 7C Vaccine Framework) experiment and view sample messages and then answer questions about their attitudes and beliefs while being monitored for eye-tracking.",[27,194],"Vaccination Promotion",[196,27,197],"Message perceptions","Immunization","2025-12-18",{"date":200,"type":34},"2025-12-22",{"date":202,"type":34},"2025-12-01",{"date":204,"type":23},"2026-09-30",{"name":206,"class":41},"University of Massachusetts, Worcester",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":55,"phases":217,"briefSummary":218,"conditions":219,"keywords":224,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":42},"100599524","neutralizing-power-of-serum-antibodies---2-100599524","NCT07085611","Neutralizing Power of Serum Antibodies - 2","Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)","PNAS-2","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Patients receiving or scheduled to receive anti-SARS-CoV-2 and\u002For anti-MPXV vaccines or monoclonal antibodies\n* Patients have provided written informed consent\n\nExclusion Criteria:\n\n* Persons under guardianship or curatorship\n* Persons under legal protection,\n* Persons persons deprived of liberty\n* Persons not affiliated to a social security scheme\n* Pregnant or breastfeeding women",{"count":216,"type":23},30,[57],"Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.",[87,220,221,27,222,223],"SARS-CoV-2 Viraemia","Monkey Pox","Serum","Mucosal Immunity",[225,226,227,27,222,228],"Neutralizing antibodies","SARS-CoV-2","Monkeypox","Mucosal immunity","2025-12-12",{"date":231,"type":34},"2025-12-19",{"date":233,"type":34},"2025-08-22",{"date":235,"type":23},"2035-07-11",{"name":237,"class":41},"Centre Hospitalier Régional d'Orléans",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":55,"phases":248,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":42},"100611436","phase-3-pandemic-influenza-vaccine-in-organ-transplantation-pivot-trial-100611436","NCT07240558","Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)","Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial): Safety and Immunogenicity of Pandemic Influenza Vaccine in Organ Transplant Recipients","PIVOT","Inclusion Criteria:\n\n* Age ≥ 18 and greater than 3 months post-transplant\n* Stable graft function\n* eGFR \\>30mL\u002Fmin\u002F1.73m2\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Allergy to vaccine components;\n* Previous life-threatening reaction to influenza vaccine (ie Guillain Barré Syndrome);\n* Ongoing or recent therapy for acute rejection (within the previous 30 days);\n* Ongoing active cytomegalovirus (CMV) infection with viral load of greater or equal to 1000 international units\u002Fml in the last 7 days;\n* Febrile illness in the past 2 weeks;\n* Rituximab in the last 6 months;\n* Receiving treatment for active or acute infection;\n* Unable to provide informed consent;\n* 2025 seasonal influenza vaccination in preceding 6 weeks;\n* Recent other vaccination in last 14 days;\n* Receipt of intravenous immunoglobulin in last 30 days or expected to receive in next 30 days; Life expectancy \\\u003C 3 months;\n* Diagnosis of influenza virus infection in the last 90 days.\n* Pregnancy known at the time of enrolment",{"count":247,"type":23},120,[249],"PHASE3","Influenza is an important pathogen in transplant recipients. The current widespread outbreak of highly pathogenic H5N1 avian influenza (HPAI) in livestock, and the occurrence of several human cases of infection suggest that the next influenza pandemic may be soon approaching. Transplant patients will likely be uniquely predisposed to serious infection with high morbidity and mortality. There are a number of important reasons that evaluation of prevention strategies are critical in this highly vulnerable population. Currently, there is no data on the immunogenicity of H5Nx vaccines in this highly vulnerable population. The investigators plan to study the safety and immunogenicity of a two-dose regimen of the pandemic influenza H5N1 vaccine in organ transplant patients.",[252,253,27],"Influenza (Pandemic)","Avian Influenza","2025-12-11",{"date":198,"type":34},{"date":257,"type":34},"2025-11-03",{"date":178,"type":23},{"name":260,"class":41},"University Health Network, Toronto",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":17,"sex":267,"minAge":268,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":55,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":42},"100613030","testing-a-biometric-identification-system-to-improve-malaria-vaccine-completion-100613030","NCT07261280","Testing a Biometric Identification System to Improve Malaria Vaccine Completion","Inclusion Criteria:\n\n* Pregnant women (in the last two trimesters), aged 15-49 years old, who do not plan to permanently move in the next 12 months.\n* Women with children under 6 months old, aged 15-49 years old, who do not plan to permanently move in the next 12 months.\n\nExclusion Criteria:\n\n* Non-age-eligible women.\n* Men and non-emancipated minors.\n* Women who do not consent.","FEMALE","15 Years","49 Years",{"count":271,"type":23},4715,[57],"Receiving all four doses of the malaria vaccine can significantly protect children against malaria illness, hospitalization, and death. However, in Ghana, only 46% of children complete the full vaccination sequence. More broadly, many children in Ghana do not receive the full set of recommended pediatric vaccinations. To address this, Simprints, in collaboration with Ghana Health Services, will implement a digital vaccination record system linked to biometrics. This system will automatically identify children who are behind on their vaccination schedule, providing health workers with information to prioritize community outreach. Additionally, it will send voice message reminders to caregivers to improve compliance. A cluster-randomized controlled trial (c-RCT) will be conducted in the Oti region to measure the impact of this innovation on the proportion of children completing malaria and routine vaccination schedules.",[27],[144,276,277,278,279],"Malaria","Adherence","Biometrics","Health Systems",{"date":281,"type":34},"2025-12-03",{"date":283,"type":34},"2025-10-15",{"date":285,"type":23},"2027-12-31",{"name":287,"class":41},"University of Michigan",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":17,"sex":18,"minAge":295,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":55,"phases":299,"briefSummary":300,"conditions":301,"keywords":304,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":319,"locationsCount":42},"100592997","vital-vaccination-immunity-time-restricted-eating-aging-and-lifestyle-100592997","NCT07000708","VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle","VITAL","Inclusion Criteria:\n\n* Male and female participants, enrolled in a 1:1 ratio\n* Age 60-85 years\n* Body mass index (BMI) 20-35 kg\u002Fm²\n* Capacity to give informed consent\n* Existing health insurance to allow evaluation and treatment of any incidental findings\n* Usual daily eating window \\> 11 hours\n* First meal of the day before 10:00 AM\n* Willingness to receive seasonal influenza and COVID-19 vaccination and proof of scheduled appointment\n* Willingness and ability to follow a prescribed TRE dietary regimen (8-hour daily eating window; 16-hour fast without any caloric intake)\n* Appointment for simultaneous influenza and COVID-19 vaccination pre-arranged with primary care physician and coordinated with study team to align with TRE intervention\n\nExclusion Criteria:\n\n* Any vaccination (especially influenza and\u002For COVID-19) within 6 months before the intervention start\n* Vaccinations not related to the study, administered during the study period from V0 to V4\n* History of influenza infection within 6 months prior to initiation of the study intervention\n* History of severe adverse reactions to prior vaccinations\n* Use of pharmacological weight-loss agents (e.g., semaglutide)\n* Diabetes mellitus under ongoing pharmacological treatment\n* Symptoms of systemic inflammatory or autoimmune disease\n* Immunosuppression (including use of immunosuppressive drugs)\n* Severe hypertension (systolic \\> 180 mmHg or diastolic \\> 110 mmHg)\n* Diseases or functional disorders which, in the opinion of the study physician, preclude participation in the study\n* Participation in any fasting intervention (e.g., TRE, alternate-day fasting, 5:2, 18:6) within 6 months before enrollment\n* Participation in another diet or weight-loss program (e.g., intensive athletic training)\n* Night-shift or rotating-shift work\n* Severe, active, or unstable medical conditions requiring treatment\n* Postoperative recovery phase\n* Antibiotic therapy within 3 months before enrollment\n* Acute or chronic infections\n* Therapeutic or medically prescribed special diets\n* Vegan diet\n* Current smoker\n* Weight change \\> 2 kg in the month before enrollment\n* Known substance, drug, or alcohol abuse\n* Anemia\n* Claustrophobia\n* Legal incapacity or any other circumstance that prevents full understanding of the nature, importance, and implications of the study","60 Years","85 Years",{"count":298,"type":23},24,[57],"The aim of this study is to investigate the effects of a four-week time-restricted eating (TRE) intervention on autophagy, immune function, and vaccine response to a seasonal influenza and COVID-19 vaccines in older healthy subjects.",[27,302,303],"Immunosenescence","Metabolism",[305,306,307,308,309,310,311,312],"fasting","vaccination","intermittent fasting","time-restricted eating","influenza","immunity","aging","immunosenescence","2025-09-17",{"date":315,"type":34},"2025-09-18",{"date":317,"type":34},"2025-09-10",{"date":127,"type":23},{"name":320,"class":41},"Charite University, Berlin, Germany",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":55,"phases":331,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":42},"100402701","phase-2-vaccination-with-autologous-dendritic-cells-loaded-with-autologous-tumour-homogenate-in-glioblastoma-100402701","NCT04523688","Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma","Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma: a Phase II Study","Combi G-Vax","After signing the informed consent form for pre-screening, patient will assess the procedures to obtain sufficient leukapheretic material for the dendritic cell vaccine manufacturing and will perform the standard radiochemotherapy treatment (Stupp regimen) for the disease.\n\nFor the pre-screening phase of the study the eligibility criteria are:\n\n1. Histologically confirmed \"monofocal\" glioblastoma\n2. Near-complete resection (= 5 ml residual tumor volume) confirmed by \"central neuroradiologist on magnetic resonance imaging (MRI) or CT scan within 72 h postoperative\"\n3. Karnofsky performance status (KPS) = 70% or performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Appendix A)\n4. Be willing and able to provide written informed consent\u002Fassent for the pre-screening phase of the trial.\n5. Be = 18 years of age on day of signing informed consent.\n6. Life expectancy of greater than 12 weeks.\n7. Patient suitable for the collection of biological material from leukapheresis:\n\n   serological tests HIV, hepatitis B virus (HBV), HCV, Treponema pallidum negative; normal cardiological parameters (ECG and cardiological examination); evaluation by transfusionist to exclude possible contraindications to leukapheresis.\n8. Patient candidate to standard radiochemotherapy (Stupp regimen)\n9. Appropriate 12-lead ECG and echocardiogram.\n\nAfter pre-screening, patient will be enrolled based on subsequent Inclusion Criteria:\n\n1. Histologically confirmed \"monofocal\" glioblastoma\n2. THE AUTOLOGOUS SURGICAL SPECIMEN NEEDED FOR VACCINE MANUFACTURING MUST HAVE BEEN COLLECTED AND SENT TO THE SOMATIC CELL THERAPY LAB OF ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO (IRCCS) AND MUST FULFIL ALL THE ACCEPTANCE CRITERIA PRESCRIBED BY THE GOOD MANUFACTURING PRACTICES (GMP) PROCEDURES.\n3. Availability of sufficient leukapheretic material for the preparation of the vaccine product.\n4. No progressive disease near-complete resection (= 5 ml residual tumor volume) confirmed by MRI after standard radiochemotherapy treatment (Stupp regimen)\n5. Patients must have recovered (grade 1 or less by CTCAE 5.0) from all the events related to previous treatments.\n6. Be willing and able to provide written informed consent\u002Fassent for the trial.\n7. Be \\>= 18 years of age on day of signing informed consent.\n8. Have a Karnofsky performance status (KPS) = 70% or a performance status of 0 or 1 on the ECOG Performance Scale.\n9. Demonstrate adequate organ and marrow function\n\nExclusion Criteria:\n\n1. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy \\> 10 mg prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n2. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n3. Has a known history of active Bacillus Tuberculosis (TB)\n4. Previous treatment with a cancer vaccine\n5. Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 5 years, except basal or squamous cell carcinoma of the skin and in situ carcinoma of the cervix uteri treated with radical surgery.\n6. Any known history of or is positivity of any serologic marker indicative of infection by Treponema pallidum, hepatitis B virus (HBsAg, HBsAb, HBcAB), hepatitis C virus (HCVAb, HCV RNA quantitative), human immunodeficiency virus (HIV), whether actual or previous.\n7. Has received a live vaccine within 30 days of planned start of study therapy.",{"count":330,"type":23},28,[332],"PHASE2","Single arm, monocentric trial to assess the safety and the progression-free survival related to the combined treatment of dendritic cell vaccine loaded with autologous tumor homogenate and temozolomide in patients operated for glioblastoma and then treated with standard radiochemotherapy (according to Stupp regimen).",[335,27],"Glioblastoma",[337,338,117,339,340,341],"glioblastoma","dendritic cells","temozolomide","Stupp regimen","cellular therapy","2025-07-17",{"date":344,"type":34},"2025-07-22",{"date":346,"type":34},"2021-03-25",{"date":348,"type":23},"2025-12",{"name":350,"class":41},"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":17,"sex":18,"minAge":357,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":55,"phases":361,"briefSummary":362,"conditions":363,"keywords":368,"overallStatus":372,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":4},"100581906","effect-of-using-educational-robots-during-vaccination-on-fear-and-pain-in-children-100581906","NCT06856395","Effect of Using Educational Robots During Vaccination on Fear and Pain in Children","Inclusion Criteria:\n\n* Volunteering to participate in the study\n* The child must be 4 years old\n* Must have come to a primary care center in Balıkesir city center\n* DaBT-İPA vaccination must be administered\n* Vastus Lateralis muscle must be used in vaccination\n\nExclusion Criteria:\n\n* Not volunteering to participate in the study\n* The child is not 4 years old\n* He\u002Fshe has not come to a family health center in Balıkesir city center\n* DaBT-İPA vaccination is not applied\n* Vastus Lateralis muscle will not be used in vaccination application","48 Months","60 Months",{"count":360,"type":23},74,[57],"Pain and fear are very common in children during vaccination. We are planning to conduct a study to help children go through this process more comfortably. The aim is to examine whether the educational robot has an effect on pain and fear during vaccination in 4-year-old children in a randomized controlled manner.",[364,365,366,27,367],"Fear","Fear of Pain","Pain","Child Behavior",[369,370,306,371],"pain","fear","child behavior","NOT_YET_RECRUITING","2025-03-06",{"date":375,"type":34},"2025-03-11",{"date":377,"type":23},"2025-03-31",{"date":379,"type":23},"2026-01-31",{"name":381,"class":41},"Balikesir University",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":18,"minAge":390,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":394,"conditions":395,"keywords":399,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":42},"100426957","dengue-vaccine-strategy-in-children-aged-9-to-17-years-in-the-french-caribbean-100426957","NCT04839757","Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean","Preparing for the Use of a Dengue Vaccine in the French Caribbean Islands of Martinique and Guadeloupe : the DengueSEA Study","DengueSEA","CHILDREN\n\nInclusion Criteria for children:\n\n* Any child aged 9 to 17 years presenting to one of the hospital departments participating in the study at the University Hospitals of Martinique or Guadeloupe\n* Need to take a blood sample or place a peripheral venous line for the management of the child\n* Residence in Martinique or Guadeloupe since at least one year\n* Information on the study given to the child and his\u002Fher parent or legal guardian\n* Collection of the parent's or legal guardian's non-objection to the child's participation\n\nExclusion Criteria for children:\n\n* Presence of fever or suspected acute infection\n* Presence of an immune deficiency or any other dysimmune condition\n\nPARENTS\n\nParental inclusion criteria (\"vaccine acceptability\" survey)\n\n* Collection of the parent's or legal guardian's non-objection to participate in the Dengvaxia® vaccine acceptability survey\n* Comprehension of spoken and written French\n\nNon-inclusion criteria for parents (vaccine acceptability survey)\n\n\\- None of the above","9 Years","17 Years",{"count":393,"type":23},590,"Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits. The 2018 European marketing authorization of the tetravalent chimeric yellow fever \u002F dengue vaccine (Dengvaxia®) is a major step forward in the fight against the disease. Dengvaxia® is indicated for the prevention of dengue due to serotypes DENV 1-4 in subjects aged 9 to 45 years with a history of infection with the dengue virus and living in endemic areas (seroprevalence of at least 70% in the target population).\n\nDengue seroprevalence data in the French Caribbean territories of Martinique and Guadeloupe dates back to 2011 and concerns only adult blood donors aged 18 to 70 years. To date, no data exists for individuals aged 9 to 17 years in the region.\n\nIn order to implement an optimal vaccine introduction strategy for these territories, the main aim of the DengueSEA study is to estimate the seroprevalence of the Dengue viruses (DENV 1-4) in 9-17 year olds giving a blood sample as part of care in hospital departments of the French Caribbean islands of Martinique and Guadeloupe.",[396,27,397,398],"Dengue","Seroprevalence","Infectious Disease",[400,401,402,403,404,405],"dengue","seroprevalence","children","adolescents","vaccination strategy","French Carribean","2025-02-20",{"date":408,"type":34},"2025-02-21",{"date":410,"type":34},"2021-06-03",{"date":412,"type":23},"2026-02",{"name":414,"class":41},"University Hospital Center of Martinique",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":55,"phases":424,"briefSummary":425,"conditions":426,"keywords":430,"overallStatus":372,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":42},"100567336","card-for-community-pharmacy-vaccinations---phase-2-100567336","NCT06666868","CARD for Community Pharmacy Vaccinations - Phase 2","CARD (Comfort Ask Relax Distract) for Community-based Pharmacy Vaccinations - Phase 2","Inclusion Criteria:\n\n* clients undergoing vaccination in participating pharmacies and providers working in participating pharmacies\n\nExclusion Criteria:\n\n* able to speak and write in English",{"count":423,"type":23},500,[57],"This study is phase 2 of a cluster trial integrating the CARD (Comfort Ask Relax System) in community pharmacies affiliated with Wholehealth Pharmacy Partners. It involves continuing CARD in pharmacies randomized to CARD in phase 1 of the trial (2023-2024 fall\u002Fwinter vaccination season), and initiating CARD in pharmacies randomized to Control (usual care) in phase 1 of the trial. Both groups will use CARD for delivery of vaccinations during the 2024-2025 fall\u002Fwinter vaccination season.",[27,427,428,429],"Vaccination Pain","Vaccination Reaction","Vaccination Pharmacy",[431,432],"vaccination reaction","vaccination experience","2024-10-29",{"date":435,"type":34},"2024-10-31",{"date":437,"type":23},"2024-11-05",{"date":439,"type":23},"2025-08-31",{"name":441,"class":41},"University of Toronto",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":11,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":55,"phases":452,"briefSummary":453,"conditions":454,"keywords":459,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":42},"100375248","phase-2-a-phase-ii-study-on-adjuvant-vaccination-with-dendritic-cells-loaded-with-autologous-tumor-homogenate-in-resected-stage-iv-rare-cancers-100375248","NCT04166006","A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.","A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS).","RaC-Ad","Inclusion Criteria:\n\n1. Patients must have histologically confirmed stage IV Head\\&Neck Squamous Cell Carcinoma (HNSCC), NeuroEndocrine Tumors (NET) or Soft Tissue Sarcoma (STS) surgically treated with radical intent.\n2. The autologous surgical specimen must have been collected and sent to the Somatic Cell Therapy Lab and must fulfil all the acceptance criteria prescribed by the Good Manufactory Practice (GMP) procedures.\n3. The patient must be disease-free, as assessed by CT scan or MRI of the chest, abdomen, pelvis performed within 60 days before enrolment. If the resected lesions occurred in other sites, these must be also included in the baseline CT scan and in all the subsequent evaluations.\n4. Patients disease-free candidates for only observation as per clinical practice (no standard treatment is available after surgery)\n5. The patient must have recovered from all the adverse events related to previous surgery.\n6. Age ≥18 years.\n7. Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1.\n8. Patient must have acceptable organ function, defined as:\n\n   1. Haemoglobin \\>10 g\u002Fdl\n   2. White blood cells ≥3000\u002Fμl.\n   3. Absolute neutrophil count ≥1500\u002Fμl.\n   4. Platelets≥75000\u002Fμl.\n   5. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C3 times the upper institutional reference level.\n   6. Total bilirubin \\\u003C1.5 times the upper institutional reference level.\n   7. Serum creatinine \\\u003C1.5 times the upper institutional reference level.\n9. Patients aged 70 years or older must have left ventricular ejection fraction not lower than 55% as assessed by echocardiography.\n10. Female patients of childbearing potential and all male patients must accept and be compliant with an highly effective contraceptive method (i.e. with a failure rate of \\\u003C1% per year: double barrier method, one barrier method plus spermicidal, intrauterine device, or oral contraception) from informed consent signature and up to three months after end of study. For this purpose are considered of childbearing potential all female subjects after puberty unless they are post-menopausal for at least two years or are surgically sterile. Complete abstinence from sexual intercourses is acceptable if patients' lifestyle guarantees his\u002Fher strict compliance with this prescription in the judgement of the Investigator.\n11. The patient is willing and able to give written informed consent for the study.\n\nExclusion Criteria:\n\n1. Patients with residual disease after surgery. Marginal resection of any lesion in the absence of clinically evident residual disease is acceptable.\n2. Patient who completed surgery more than 90 days before study enrolment.\n3. History of other neoplastic diseases in the previous 5 years, except basal cell carcinoma of the skin and in situ carcinoma of the cervix uteri treated with curative surgery.\n4. History of congenital or acquired immunodeficiency, including history of organ transplantation.\n5. Any positivity for the serologic markers of hepatitis B virus (HBV) (including at least anti- Hepatitis B surface antibodies (HBs) and hepatitis B core (HBc) antibodies, hepatitis C virus (HCV), HIV or Treponema pallidum. The serologic tests must have been performed within 30 days before any GMP-regulated activity (i.e. surgical resection and leukapheresis). The sole positivity for antibodies against the HBV surface antigen (i.e.\n\n   with all other HBV markers negative) is indicative of previous HBV vaccination and therefore is acceptable.\n6. Female patients who are pregnant or nursing.\n7. Participation in another clinical trial with any investigational agent within 30 days prior to study screening.\n8. Any active inflammatory or autoimmune disease requiring systemic steroids or other immunomodulatory agents as detailed in section 6.4, or potentially requiring such treatments during the study treatment in the judgement of the Investigator.\n9. Any clinical condition that, in the opinion of the Investigator or the Transfusion Medicine specialist, is a contraindication to leukapheresis. In addition, all patients aged 70 or older must be evaluated by a cardiology specialist before the procedure to exclude any clinically relevant cardiac condition and any grade 3-4 cardiac arrhythmia, even if asymptomatic.\n10. Any uncontrolled serious intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations potentially impacting patient safety and compliance in the opinion of the Investigator.\n11. Refusal of giving written informed consent.",{"count":451,"type":23},51,[332],"Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In Head\u002FNeck tumors (H\\&N), NEuroendocrine Tumors (NET) and Soft Tissue Sarcomas (STS).",[455,456,457,458,27],"Head Neck Tumors","Neuroendocrine Tumors","Soft Tissue Sarcoma","Rare Cancer",[455,456,457,460,306,461,462,463],"rare cancer","autologous dendritic cells","adjuvant","Interleukin-2","2024-09-17",{"date":466,"type":34},"2024-09-19",{"date":468,"type":34},"2019-12-12",{"date":470,"type":23},"2031-12",{"name":350,"class":41},{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":55,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":42},"100528996","covid-19-vaccine-effectiveness-against-recurrent-infection-among-lung-cancer-patients-and-biomarker-research-100528996","NCT06168032","COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research","Efficacy of COVID-19 Booster-Dose Vaccine for Re-infection Precaution and Dynamics of Specific Serum Antibodies in the Management of Lung Cancer Patients With Systemic Anti-cancer Treatment","Inclusion Criteria:\n\n1. Patients who agree to participate in the trial and sign the informed consents.\n2. Male or female, ≥18 years old.\n3. Diagnosed of lung carcinoma by histological and cytological examinations.\n4. Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy.\n5. Recorded history of COVID19 infection.\n6. Sufficiently functional organs.\n7. Eastern Cooperative Oncology Group performance score (PS) ranging from 0 to 2.\n\nExclusion Criteria:\n\n1. Life expectance less than 3 months.\n2. Less than 3 months since last confirmed COVID-19 infection.\n3. Patients unable to return the hospital for follow-up.\n4. Patients allergic to COVID-19 vaccine.\n5. Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or immunization except recoverable granulocytopenia.",{"count":480,"type":23},1224,[57],"A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.",[484,485,27,486,487,488],"COVID-19 Recurrent","Lung Cancer","Antibody","Chemotherapy","Immune Checkpoint Inhibitor","2023-12-11",{"date":491,"type":34},"2023-12-13",{"date":493,"type":23},"2023-12-08",{"date":495,"type":23},"2026-12-08",{"name":497,"class":41},"Peking Union Medical College Hospital",{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":507,"conditions":508,"keywords":509,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":42},"100352963","post-vaccination-biological-collection-100352963","NCT03875703","Post-Vaccination Biological Collection","Biological Collection for Studying Vaccine-induced Immune Responses","BioCol-VIR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Informed and consented\n* Need to be vaccinated for routine care\n\nExclusion Criteria:\n\n* Person under guardianship or safeguards\n* Pregnant or breastfeeding woman\n* No affiliation to a health insurance scheme",{"count":84,"type":23},"Introduction: Vaccination is a powerful weapon in the fight against infectious diseases, which has led to dramatic reduction in mortality and complications from some diseases. In this respect, vaccination is a real worldwide public health challenge (WHO). Thus, vaccine research benefits from an exponential development of knowledge in immunology and biotechnology. In particular, the advent of recent tools (\"omics\", new cytometric assays) and the description of new categories of immune cells (Tfh, BReg...) have revolutionized the characterization of immune responses, particularly post-vaccination. To study of the immune response following vaccination remains essential in order to define the immunological correlates to vaccine protection. This response also varies according to parameters related to the vaccine (type, adjuvant, dose, regimen…) and to the vaccinated host (genetics, age, morbidity, treatment …). Analyzing with new generation immune assays, new data on immunological responses post-vaccination from a clinical cohort is therefore essential to better define these correlates.\n\nObjective: To develop new vaccines (HIV, emerging infectious diseases) the investigators use a \"System vaccinology\" method to decipher the mechanisms of immune responses set up against vaccines currently being developed or marketed, specifically in specific populations (patients with primary immune deficiency, sickle cell patients, solid organ transplanted patients, COPD).\n\nMethod: Description of the genetic, molecular and cellular mechanisms of the immune response to vaccines recommended for adults, in particular influenza and pneumococcal vaccines, but also other mandatory vaccines (MMR,...) or vaccine for travelers (yellow fever, ...) as part of routine care in different population categories (healthy subjects, HIV+ subjects, COPD patients, …), using qualitative and quantitative immunological assays: transcriptional analysis of the dynamic innate immune response, analysis of the lymphocytes B \\& T responses (phenotype, repertoire analysis, functional analysis including T reg and TFH populations, antibody response), genetic analysis in the context of primary immune deficiencies) Conclusion: The data generated will allow the best possible analysis of vaccine responses according to vaccines and vaccinated populations, providing important information for the research developed within the department.",[27,92],[510,27,511],"Biological Collection","Active Immune Response","2020-12-11",{"date":514,"type":34},"2020-12-14",{"date":516,"type":34},"2019-09-01",{"date":518,"type":23},"2030-02-01",{"name":520,"class":41},"Assistance Publique - Hôpitaux de Paris"]